Ingrid Michon is a Consultant at SGS Exprimo. Ingrid obtained her PhD degree from the University of Leiden, the Netherlands with an emphasis on drug targeting in vascular disease and her MS degree in Medical Biology from the Catholic University of Nijmegen, the Netherlands. After her PhD she worked as a postdoc at the Division of Biopharmaceutics on a NWO Genomics Grant: Genes and pathways critical in the development of atherosclerosis. After that, she worked for the Medicines Evaluation Board in the Netherlands as a Regulatory Affairs manager before moving to Astellas Pharma Europe. Here she worked as a PK scientist within Clinical Pharmacology and Exploratory Development for 12 years. While being a PK scientist, she was also responsible for DDI assessments of new compounds and acted as the Clinical Pharmacology Lead for an anti-infective drug during European submission. During her time at Astellas, she obtained experience in all developmental stages, with a focus on Phase I, Phase IV, PIP and paediatric studies. She has experience in working in therapeutic areas such as Oncology, Infectious diseases, Urology, Nephrology and Women’s Diseases. Recent years, her main role was the implementation of PBPK within Astellas Europe, exploring the prediction of food effect and other absorption related questions.
Ingrid joined Exprimo in 2019 and lives near Leiden, the Netherlands.